A 47-Year-Old Woman with EGFR-mutated Advanced/Metastatic NSCLC

The FDA cleared the investigational new drug application for MRANK-106, a dual WEE1/YES1 kinase inhibitor, targeting advanced solid tumors.

Antonious Hazim, MD, shares insights on his journey into oncology, his experiences at the Mayo Clinic, and his ongoing research.

225Ac-SSO110 has now received FDA orphan drug designation and investigational new drug application clearance for the treatment of SCLC.

In season 4, episode 12 of Targeted Talks, Federico Albrecht, MD, gives and account of 2 cases of patients with small cell lung cancer and how these patients were treated.

The FDA has approved the investigational new drug application of 225Ac-SSO110, allowing for the start of a phase 1/2 trial in patients with extensive-stage small cell lung cancer and Merkel cell carcinoma.

The investigational new drug application for the nanoparticle drug SNB-101 has been cleared for small cell lung cancer treatment.